Indaptus Therapeutics, Inc. Research and Development Expense
Indaptus Therapeutics, Inc. (INDP) reported Research and Development Expense of $363.13 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Indaptus Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $363.13K, a 83.24% decline year-over-year.
- Indaptus Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $491.13K, a 82.53% decline year-over-year.
- Indaptus Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $2.85M, a 14.73% increase year-over-year.
- Indaptus Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $1.52M, a 3.53% increase year-over-year.
- Indaptus Therapeutics, Inc. research and development expense for fiscal 2025 was $9.34M, a 28.82% increase from fiscal 2024.
- Indaptus Therapeutics, Inc. research and development expense for fiscal 2024 was $7.25M, a 4.86% decline from fiscal 2023.
- Indaptus Therapeutics, Inc. research and development expense for fiscal 2023 was $7.62M, a 20.51% increase from fiscal 2022.
- Indaptus Therapeutics, Inc. research and development expense for fiscal 2022 was $6.32M, a 150.66% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $363.13K 10-Q · filed 2026-08-13 | $854.26K 10-Q · filed 2026-08-13 | $3.70M derived: sum of 3 quarters · filed 2026-08-13 | $5.22M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $491.13K 10-Q · filed 2026-05-15 | $3.34M derived: sum of 2 quarters · filed 2026-05-15 | $4.85M derived: sum of 3 quarters · filed 2026-05-15 | $7.02M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.36M derived: sum of 2 quarters · filed 2026-03-17 | $6.53M derived: sum of 3 quarters · filed 2026-08-13 | $9.34M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $1.52M 10-Q · filed 2025-11-12 | $3.68M derived: sum of 2 quarters · filed 2026-08-13 | $6.50M 10-Q · filed 2025-11-12 | $8.98M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $2.17M 10-Q · filed 2026-08-13 | $4.98M 10-Q · filed 2026-08-13 | $7.46M derived: sum of 3 quarters · filed 2026-08-13 | $8.92M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $2.81M 10-Q · filed 2026-05-15 | $5.29M derived: sum of 2 quarters · filed 2026-05-15 | $6.76M derived: sum of 3 quarters · filed 2026-05-15 | $8.47M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.95M derived: sum of 2 quarters · filed 2026-03-17 | $5.66M derived: sum of 3 quarters · filed 2026-03-17 | $7.25M 10-K · filed 2026-03-17 | ||
| 2024-09-30 | $1.47M 10-Q · filed 2025-11-12 | $3.18M derived: sum of 2 quarters · filed 2025-11-12 | $4.77M 10-Q · filed 2025-11-12 | $6.81M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $1.71M 10-Q · filed 2025-08-13 | $3.31M 10-Q · filed 2025-08-13 | $5.34M derived: sum of 3 quarters · filed 2025-08-13 | $7.57M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $1.59M 10-Q · filed 2025-05-14 | $3.63M derived: sum of 2 quarters · filed 2025-05-14 | $5.85M derived: sum of 3 quarters · filed 2025-05-14 | $7.33M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $4.26M derived: sum of 2 quarters · filed 2025-03-13 | $5.74M derived: sum of 3 quarters · filed 2025-03-13 | $7.62M 10-K · filed 2025-03-13 | ||
| 2023-09-30 | $2.23M 10-Q · filed 2024-11-12 | $3.71M derived: sum of 2 quarters · filed 2024-11-12 | $5.59M 10-Q · filed 2024-11-12 | $7.50M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $1.48M 10-Q · filed 2024-08-12 | $3.36M 10-Q · filed 2024-08-12 | $5.27M derived: sum of 3 quarters · filed 2024-08-12 | $6.88M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $1.88M 10-Q · filed 2024-05-08 | $3.79M derived: sum of 2 quarters · filed 2024-05-08 | $5.40M derived: sum of 3 quarters · filed 2024-05-08 | $6.91M derived: sum of 4 quarters · filed 2024-05-08 | ||
| 2022-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $3.52M derived: sum of 2 quarters · filed 2024-03-13 | $5.03M derived: sum of 3 quarters · filed 2024-03-13 | $6.32M 10-K · filed 2024-03-13 | ||
| 2022-09-30 | $1.61M 10-Q · filed 2023-11-06 | $3.12M derived: sum of 2 quarters · filed 2023-11-06 | $4.41M 10-Q · filed 2023-11-06 | $5.36M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2022-06-30 | $1.51M 10-Q · filed 2023-08-14 | $2.80M 10-Q · filed 2023-08-14 | $3.75M derived: sum of 3 quarters · filed 2023-08-14 | $4.45M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $1.30M 10-Q · filed 2023-05-11 | $2.24M derived: sum of 2 quarters · filed 2023-05-11 | $2.94M derived: sum of 3 quarters · filed 2023-05-11 | $3.33M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $944.64K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $1.64M derived: sum of 2 quarters · filed 2023-03-17 | $2.03M derived: sum of 3 quarters · filed 2023-03-17 | $2.52M 10-K · filed 2023-03-17 | ||
| 2021-09-30 | $697.67K 10-Q · filed 2022-11-10 | $1.09M derived: sum of 2 quarters · filed 2022-11-10 | $1.58M 10-Q · filed 2022-11-10 | $1.93M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $391.12K 10-Q · filed 2022-08-08 | $1.81M 10-Q · filed 2021-08-16 | $880.84K 10-Q · filed 2022-08-08 | $3.96M 10-Q · filed 2021-08-16 | $1.23M derived: sum of 3 quarters · filed 2022-08-08 | $2.58M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $489.72K 10-Q · filed 2022-05-12 | $841.86K derived: sum of 2 quarters · filed 2022-05-12 | $2.19M derived: sum of 3 quarters · filed 2022-05-12 | $3.47M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $352.13K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.70M derived: sum of 2 quarters · filed 2022-03-21 | $2.98M derived: sum of 3 quarters · filed 2022-03-21 | $2.66M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $1.35M 10-Q · filed 2021-11-15 | $2.62M derived: sum of 2 quarters · filed 2021-11-15 | $2.30M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $1.27M 10-Q · filed 2021-08-16 | $3.30M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |